Waon therapy improves the prognosis of patients with chronic heart failure

被引:43
|
作者
Kihara, Takashi [1 ]
Miyata, Masaaki [1 ]
Fukudome, Tsuyoshi [1 ]
Ikeda, Yoshiyuki [1 ]
Shinsato, Takuro [1 ]
Kubozono, Takuro [1 ]
Fujita, Shoji [1 ]
Kuwahata, So [1 ]
Hamasaki, Shuichi [1 ]
Torii, Hiroyuki [2 ]
Lee, Soki [3 ]
Toda, Hitoshi [3 ]
Tei, Chuwa [1 ]
机构
[1] Kagoshima Univ, Grad Sch Med, Dept Cardiovasc Resp & Metab Med, Kagoshima 8908520, Japan
[2] Kagoshima City Med Assoc Hosp, Dept Cardiol, Kagoshima, Japan
[3] Kagoshima City Hosp, Dept Cardiol, Kagoshima, Japan
关键词
Waon therapy; Prognosis; Heart failure; OXIDE SYNTHASE EXPRESSION; REPEATED SAUNA TREATMENT; THERMAL THERAPY; CARDIOMYOPATHIC HAMSTERS; MORTALITY; SURVIVAL; DISEASE; TRIAL;
D O I
10.1016/j.jjcc.2008.11.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We developed a Waon therapy (soothing warm therapy) and have previously reported that repeated Waon therapy improves hemodynamics, peripheral vascular function, arrhythmias, and clinical symptoms in patients with chronic heart failure (CHF). The aim of this study was to investigate the effect of Waon therapy on the prognosis of CHF patients. Patients and methods: We studied 129 patients with CHF in NYHA functional class III or IV who were admitted to our hospital between January 1999 and March 2001. In the Waon therapy group, 64 patients were treated with a far infrared-ray dry sauna at 60 degrees C for 15 min and then kept on bed rest with a blanket for 30 min. The patients were treated daily for 5 days during admission, and then at least twice a week after discharge. In the control group, 65 patients, matched for age, gender, and NYHA functional class, were treated with traditional CHF therapy. The follow-up time was scheduled for 5 years. Results: Recent, complete follow-up data on each patient were obtained. The overall survival rate was 84.5% (Kaplan-Meier estimate). Twelve patients died in the control group and 8 patients died in the Waon therapy group at 60 months of follow-up. Cardiac events due to heart failure or cardiac death occurred in 68.7% of the control group but only 31.3% of the Waon therapy group (P < 0.01) at 60 months of follow-up. Conclusion: Waon therapy reduced cardiac events in patients with CHF. This therapy is a promising non-pharmacological treatment for CHF. (C) 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:214 / 218
页数:5
相关论文
共 50 条
  • [31] Hospitalisation length and prognosis in heart failure patients
    Zaprutko, Joanna
    Michalak, Michal
    Nowicka, Anna
    Dankowski, Rafal
    Drozdz, Jaroslaw
    Ponikowski, Piotr
    Opolski, Grzegorz
    Nessler, Jadwiga
    Nowalany-Kozielska, Ewa
    Szyszka, Andrzej
    KARDIOLOGIA POLSKA, 2017, 75 (04) : 323 - 331
  • [32] Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial
    Massie, Barry M.
    Collins, Joseph F.
    Ammon, Susan E.
    Armstrong, Paul W.
    Cleland, John G. F.
    Ezekowitz, Michael
    Jafri, Syed M.
    Krol, William F.
    O'Connor, Christopher M.
    Schulman, Kevin A.
    Teo, Koon
    Warren, Stuart R.
    CIRCULATION, 2009, 119 (12) : 1616 - 1624
  • [33] THE PROGNOSIS OF PATIENTS WITH CHRONIC HEART FAILURE, DEPENDING ON ADHERENCE TO OBSERVATION IN A SPECIALIZED HEART FAILURE TREATMENT CENTER
    Vinogradova, N. G.
    KARDIOLOGIYA, 2019, 59 (10) : 13 - 21
  • [34] Chronic renal impairment in patients with Chagas cardiomyopathy with chronic systolic heart failure: Prevalence and prognostic significance
    Ardito, Sabrina Q.
    Bestetti, Reinaldo B.
    Cardinalli-Neto, Augusto
    Otaviano, Ana R.
    Nogueira, Paulo R.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 152 (01) : 133 - 134
  • [35] Impact of Longitudinal Myocardial Deformation on the Prognosis of Chronic Heart Failure Patients
    Nahum, Julien
    Bensaid, Alexandre
    Dussault, Caroline
    Macron, Laurent
    Clemence, Darrort
    Bouhemad, Belaid
    Monin, Jean-Luc
    Rande, Jean-Luc Dubois
    Gueret, Pascal
    Lim, Pascal
    CIRCULATION-CARDIOVASCULAR IMAGING, 2010, 3 (03) : 249 - 256
  • [36] Thymopentin improves cardiac function in older patients with chronic heart failure
    Cao Xiaojing
    Li Yanfang
    Guo Yanqing
    Cao Fangfang
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2017, 17 (01): : 24 - 30
  • [37] TELEMONITORING IN PATIENTS WITH CHRONIC HEART FAILURE
    Mareev, Yu, V
    Zinchenko, A. O.
    Myasnikov, R. P.
    Vakhovskaya, T. V.
    Andreenko, E. Yu
    Boytsov, S. A.
    Drapkina, O. M.
    KARDIOLOGIYA, 2019, 59 (09) : 4 - 15
  • [38] Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure
    Chorianopoulos, Emmanuel
    Rosenberg, Mark
    Zugck, Christian
    Wolf, Johanna
    Katus, Hugo A.
    Frey, Norbert
    EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (11) : 1050 - 1056
  • [39] Impact of chronic obstructive pulmonary disease severity on symptoms and prognosis in patients with systolic heart failure
    Arnaudis, Brice
    Lairez, Olivier
    Escamilla, Roger
    Fouilloux, Audrey
    Fournier, Pauline
    Monteil, Benoit
    Bouisset, Frederic
    Arnal, Jean-Francois
    Elbaz, Meyer
    Carrie, Didier
    Roncalli, Jerome
    Pathak, Atul
    Galinier, Michel
    CLINICAL RESEARCH IN CARDIOLOGY, 2012, 101 (09) : 717 - 726
  • [40] Usefulness of hypochloremia at the time of discharge to predict prognosis in patients with chronic heart failure after hospitalization
    Misumi, Kayo
    Matsue, Yuya
    Nogi, Kazutaka
    Fujimoto, Yudai
    Kagiyama, Nobuyuki
    Kasai, Takatoshi
    Kitai, Takeshi
    Oishi, Shogo
    Akiyama, Eiichi
    Suzuki, Satoshi
    Yamamoto, Masayoshi
    Kida, Keisuke
    Okumura, Takahiro
    Nogi, Maki
    Ishihara, Satomi
    Ueda, Tomoya
    Kawakami, Rika
    Saito, Yoshihiko
    Minamino, Tohru
    JOURNAL OF CARDIOLOGY, 2025, 85 (03) : 235 - 240